Original Article
Inhibition of the Bcl-xL Deamidation Pathway in Myeloproliferative Disorders
N Engl J Med 2008; 359:2778-2789December 25, 2008
- Abstract
Background
The myeloproliferative disorders are clonal disorders with frequent somatic gain-of-function alterations affecting tyrosine kinases. In these diseases, there is an increase in DNA damage and a risk of progression to acute leukemia. The molecular mechanisms in myeloproliferative disorders that prevent apoptosis induced by damaged DNA are obscure.
Methods
We searched for abnormalities of the proapoptotic Bcl-xL deamidation pathway in primary cells from patients with chronic myeloid leukemia (CML) or polycythemia vera, myeloproliferative disorders associated with the BCR-ABL fusion kinase and the Janus tyrosine kinase 2 (JAK2) V617F mutation, respectively.
Results
The Bcl-xL deamidation pathway was inhibited in myeloid cells, but not T cells, in patients with CML or polycythemia vera. DNA damage did not increase levels of the amiloride-sensitive sodium–hydrogen exchanger isoform 1 (NHE-1), intracellular pH, Bcl-xL deamidation, and apoptosis. Inhibition of the pathway was reversed by enforced alkalinization or overexpression of NHE-1, leading to a restoration of apoptosis. In patients with CML, the pathway was blocked in CD34+ progenitor cells and mature myeloid cells. Imatinib or JAK2 inhibitors reversed inhibition of the pathway in cells from patients with CML and polycythemia vera, respectively, but not in cells from a patient with resistance to imatinib because of a mutation in the BCR-ABL kinase domain.
Conclusions
BCR-ABL and mutant JAK2 inhibit the Bcl-xL deamidation pathway and the apoptotic response to DNA damage in primary cells from patients with CML or polycythemia vera.
Media in This Article
Figure 1
Inhibition of the NHE-1–Bcl-xL Deamidation Pathway Induced by DNA Damage in CML Cells.Figure 2
Inhibition of the NHE-1–Bcl-xL Deamidation Pathway in Polycythemia Vera Cells Induced by DNA Damage.Article Activity
- Article
Chronic myeloid leukemia (CML) and polycythemia vera are clonal myeloproliferative disorders that are associated with the activation of distinct tyrosine kinases, the BCR-ABL fusion kinase1 and the Janus tyrosine kinase 2 (JAK2) mutation,2,3 respectively. In both disorders, patients usually present with chronic disease, which is readily controlled. However, for reasons that are unclear, both diseases carry a risk of progression to a blastic phase resembling acute leukemia that resists further therapy. The cellular prosurvival protein Bcl-xL is up-regulated in patients with CML and polycythemia vera and is thought to inhibit apoptosis.4-7 Moreover, BCR-ABL protein expression is associated with a reduced apoptotic response to genotoxic drugs,8 and quiescent CML stem cells, thought to be responsible for residual disease, are resistant to the apoptosis that tyrosine kinase inhibitors induce.9-11
A pathway regulating the function of Bcl-xL has been described in several studies.12-14 In normal mouse thymocytes, DNA damage increases the activity of the amiloride-sensitive sodium–hydrogen exchanger isoform 1 (NHE-1), thus raising the intracellular pH, which in turn causes nonenzymatic deamidation of Bcl-xL. In this context, the importance of deamidation (the removal of an amide functional group from an organic compound) is due to its conversion of the amino acid asparagine into isoaspartic acid. Such an alteration reduces the ability of the antiapoptotic Bcl-xL protein to sequester and inhibit the Bcl-2 homology 3 (BH3)–only family of proapoptotic proteins, thereby promoting apoptosis. A link with tumorigenesis was suggested by the observation that the normal response of the NHE-1–Bcl-xL pathway to DNA damage was abolished in a mouse model of T-cell lymphoma.13,14 Thymocytes that were transformed by an activated Lck tyrosine kinase were unable to respond to DNA damage by increasing NHE-1 levels, Bcl-xL deamidation, or apoptosis. Inhibition of the NHE-1–Bcl-xL pathway does not appear to be a general feature of cancer, since Bcl-xL deamidation that is induced by damaged DNA is intact in cell lines of osteosarcoma and cervical, bladder, and ovarian cancers12,15 and in primary chronic lymphocytic leukemia cells.14 Because the relevance of Bcl-xL deamidation for human cancers associated with activated tyrosine kinases remains unclear, we examined the Bcl-xL deamidation pathway in cells from patients with CML and polycythemia vera.
Methods
Reagents and Antibodies
We obtained etoposide, propidium iodide, and nigericin from Sigma; SNARF-1 from Molecular Probes; imatinib from Novartis; JAK inhibitor 1 from Calbiochem; and JAK2 inhibitors TG101209 and AT9283 from Astex Therapeutics. For Western blot analysis, we used antibodies Bcl-xL (610212) and NHE-1 (clone 54) from BD Transduction Laboratories and β-actin and α-tubulin from Sigma. For flow cytometry, we used antibodies CD2-FITC (product code, CD0201), CD3-FITC (product code, MHCD0301), CD19-FITC (product code, MHCD1901), CD13-PE (product code, MHCD1304), and CD14-APC (product code, MHCD1405) (Caltag).
Patients
We collected peripheral-blood samples from patients with either CML or polycythemia vera and from healthy control subjects. All subjects provided written informed consent. The study was approved by the Cambridge and Eastern Region ethics committee. Of the 10 CML samples for which data are presented in Figure 1Figure 1
Inhibition of the NHE-1–Bcl-xL Deamidation Pathway Induced by DNA Damage in CML Cells., 6 were from patients with newly diagnosed chronic-phase CML, 1 was from a patient in the accelerated phase, and 3 were from patients in the chronic phase who were receiving therapy. All patients with polycythemia vera whose data are presented in Figure 2Figure 2Inhibition of the NHE-1–Bcl-xL Deamidation Pathway in Polycythemia Vera Cells Induced by DNA Damage. had stable, nontransformed disease and were receiving hydroxycarbamide therapy at the time of blood sampling. The six patients with CML whose data are presented in Figure 3Figure 3
The Effect of Imatinib or JAK2 Inhibitors on NHE-1 Up-Regulation and Bcl-xL Deamidation in CML Cells Induced by DNA Damage. had newly diagnosed chronic-phase CML, and the patient with the imatinib resistance mutation (E255V) in Figure 4Figure 4
Effect of Imatinib Resistance on the NHE-1–Bcl-xL Pathway Induced by DNA Damage in CML Cells. was in the accelerated phase. All patients with CML had the BCR-ABL rearrangement; patients with polycythemia vera and idiopathic myelofibrosis had received a diagnosis on the basis of criteria that have been reported previously.2 The quantitative pyrosequencing assay for the JAK2 V617F mutation was performed as described previously.16 Cell Purification
Peripheral-blood samples from the patients and control subjects were centrifuged through Lymphoprep (Axis-Shield PoC), and the cells in the pellets (granulocytes) or the interphase (peripheral-blood mononuclear cells [PBMCs]) were then harvested for subsequent experiments. The myeloid origin of PBMCs and the purity of the granulocyte populations were checked by staining with CD2, CD3, and CD19 monoclonal antibodies, conjugated with fluorescein isothiocyanate, together with CD13-PE and CD14-APC, followed by flow cytometry. Of the PBMCs, 85 to 95% were of myeloid origin, and the granulocytes were more than 90% pure. (Representative flow cytometric data of cell preparations are shown in Figure 1 in the Supplementary Appendix, available with the full text of this article at www.nejm.org.) Mobilized peripheral-blood samples from control subjects and samples of CML peripheral blood were used to purify CD34+ cells, first using a MACS CD34 MicroBead Kit (Miltenyi Biotec), followed by cell sorting to obtain 95% pure CD34+ cells maintained in RPMI medium with 10% fetal-calf serum.
Cell Lines
We used human hematopoietic cancer-cell lines K562, HEL, Daudi, DU528, Jum2, Karpas299, OPM2, and DOHH2 (for details, see Table 1 in the Supplementary Appendix). Cells were cultured in RPMI medium with 10% fetal-calf serum. Murine BaF3 cells expressing the thrombopoietin receptor (BaF3–TpoR) were cultured in RPMI medium with 10% fetal-calf serum containing 1 ng per milliliter of recombinant interleukin-3.
DNA Damage Treatments
Cells were irradiated with 5 Gy with the use of a cesium source or treated with 50 μM of etoposide in dimethyl sulfoxide (DMSO) for the times indicated. Carrier DMSO was added to control cells.
Immunoblotting and Measures of pH and Apoptosis
These analyses were performed as described previously.14 Intracellular pH was measured with the use of a pH-sensitive dye in conjunction with flow cytometry.
Transfection and Retroviral Transduction
Peripheral-blood mononuclear cells from patients with CML were transfected with plasmid NHE-1–internal ribosome entry site–enhanced green fluorescent protein (pNHE-1–IRES–EGFP) with the use of a Nucleofector kit (K562) (Amaxa Biosystems). GFP-positive cells were sorted by flow cytometry with the use of a FACSAria flow cytometer (BD Biosciences). Murine stem-cell virus–IRES–GFP–based retroviral vectors MIG-BCR-ABL, MIG-Jak2v617f, and MIG-NPM-ALK were transfected into the Phoenix cell line with the use of Lipofectamine (Invitrogen), and culture supernatants were harvested 24 hours later. Viral infection of Baf3–TpoR cells was performed by spinoculation (1200 g for 90 minutes at 30°C). GFP-positive cells were cultured in RPMI medium with 10% fetal-calf serum and sorted 2 days later by flow cytometry with the use of a FACSAria flow cytometer.
Statistical Analysis
We performed all statistical analyses using Student's t-test. All P values are two-sided. A P value of less than 0.05 was considered to indicate statistical significance.
Results
DNA Damage
To assess the activity of the NHE–1–Bcl-xL pathway in normal myeloid cells, we studied the effect of DNA damage on purified peripheral-blood granulocytes from healthy control subjects. Both etoposide and irradiation increased levels of NHE-1, intracellular pH, deamidation of Bcl-xL, and the percentage of apoptotic cells, findings that were consistent with results in mouse thymocytes that were reported previously.14 However, no reproducible changes in basal NHE-1 levels were apparent (Figure 1A, and Figure 2 in the Supplementary Appendix). In marked contrast, we did not see such responses to DNA damage in granulocytes from patients with CML carrying the BCR-ABL tyrosine kinase (Figure 1A and 1B). Both etoposide and irradiation caused significantly less apoptosis in CML granulocytes than in normal granulocytes (Figure 1C), which was consistent with the genotoxic resistance for BCR-ABL–positive cells reported previously.8 In contrast, T lymphocytes from the same patients with CML did not resist alkalinization, Bcl-xL deamidation, and apoptosis induced by damaged DNA (Figure 3 in the Supplementary Appendix).
To investigate the level at which the NHE-1–Bcl-xL deamidation pathway was blocked in CML cells, we exposed granulocytes from patients with CML to varying levels of external pH. Enforced alkalinization reversed the inhibition and restored Bcl-xL deamidation and apoptosis even in the absence of DNA damage, suggesting that the block was at the level of the NHE-1 antiport (Figure 4 in the Supplementary Appendix). Consistent with this interpretation, transfection of NHE-1 complementary DNA (cDNA) into CML cells resulted in an increase in NHE-1 levels by a factor of 2 to 3 and was accompanied by increased intracellular pH, Bcl-xL deamidation, and apoptosis (Figure 1D to 1F).
We next studied patients with polycythemia vera, a disease that is associated with a gain-of-function point mutation in the cytoplasmic tyrosine kinase JAK2.17-20 Since peripheral-blood granulocytes and bone marrow progenitors from many patients with polycythemia vera contain a mixture of normal and mutant cells,17,21 we selected patients in whom JAK2 pyrosequencing demonstrated that the majority of peripheral-blood granulocytes carried the JAK2 mutation (Figure 5 in the Supplementary Appendix). In contrast to granulocytes from control subjects, those from all eight patients with polycythemia vera who fulfilled these criteria consistently did not have a response to DNA damage by increasing NHE-1 levels, intracellular pH, or Bcl-xL deamidation (Figure 2A to 2C). In addition, both etoposide and irradiation produced significantly less apoptosis in polycythemia vera granulocytes than in normal granulocytes (Figure 2D). In contrast to the granulocytes, T cells from the same patients showed no defect in DNA damage–induced Bcl-xL deamidation, intracellular alkalinization, or apoptosis (Figure 3 in the Supplementary Appendix).
As with CML cells, enforced alkalinization of polycythemia vera granulocytes overcame inhibition of the NHE-1–Bcl-xL deamidation pathway and was accompanied by increased Bcl-xL deamidation and apoptosis (Figure 6 in the Supplementary Appendix). The Bcl-xL deamidation pathway was also inhibited in granulocytes from two patients with idiopathic myelofibrosis with the JAK2 V617F mutation but not in two patients with this disease without the JAK2 mutation (Figure 7 in the Supplementary Appendix).
To elucidate further the correlation between tyrosine kinase expression and inhibition of the NHE-1–Bcl-xL pathway, we investigated eight cell lines representing different hematologic cancers associated with distinct molecular mechanisms (Table 1 and Figure 8 in the Supplementary Appendix). The NHE-1–Bcl-xL pathway was inhibited in K562 cells carrying BCR-ABL and derived from a patient with CML in blast crisis and also in human erythroleukemia (HEL) cells, which carry the JAK2 V617F mutation and were derived from a patient with acute myeloid leukemia. These data suggest that the pathway remains inhibited after leukemic transformation, which was confirmed using blasts from a patient with CML in blast crisis (data not shown). In contrast, the pathway was intact in four other cell lines that are not thought to express oncogenic tyrosine kinases (Table 1 and Figure 8 in the Supplementary Appendix). The pathway was also intact in a T-lymphoma cell line (Karpas-299), which expresses the NPM-ALK tyrosine kinase fusion protein, and in a myeloma cell line (OPM-2), which overexpresses the fibroblast growth factor receptor 3 (FGFR3) tyrosine kinase. These results suggest that inhibition of the Bcl-xL deamidation pathway is not a general feature of hematologic cancers and is mediated by a subgroup of tyrosine kinases or is dependent on a particular cellular context.
To address whether inhibition of the NHE-1–Bcl-xL pathway is influenced by kinase strength, we performed a series of experiments using a Baf3–TPoR cell line transduced with BCR-ABL, JAK2 V617F, or NPM-ALK tyrosine kinases, giving rise to several cell populations with varying kinase expression levels (Figure 9 in the Supplementary Appendix). Levels of BCR-ABL and JAK2 V617F expression correlated well with the degree of inhibition of the Bcl-xL deamidation pathway, whereas NPM-ALK caused no inhibition even at its highest expression level.
Both CML and polycythemia vera are thought to arise from a transformed multipotent stem cell. BCR-ABL is expressed at high levels in stem and progenitor cells and induces expansion of the progenitor compartment during chronic-phase CML.22-24 We therefore assessed the status of the NHE-1–Bcl-xL pathway in normal and CML progenitors that expressed the CD34 stem-cell antigen. In normal CD34+ cells, but not in those derived from patients with CML, etoposide treatment increased NHE-1 levels, Bcl-xL deamidation, intracellular alkalinization, and apoptosis (Figure 3A to 3C). Furthermore, in normal CD34+ cells, apoptosis that was triggered by DNA damage was significantly inhibited by dimethylamiloride, a selective NHE-1 antiport inhibitor (Figure 10 in the Supplementary Appendix). These data demonstrate that the Bcl-xL deamidation pathway operates in normal CD34+ cells and is inhibited in CD34+ cells from patients with CML.
We next addressed whether inhibition of the Bcl-xL deamidation pathway was dependent on aberrant kinase activity. Granulocytes from three patients with polycythemia vera were exposed to three different JAK2 inhibitors. All three inhibitors reversed the block of the pathway: Bcl-xL deamidation, intracellular pH, and apoptosis all increased in response to DNA damage (Figure 3D, and Figure 11 in the Supplementary Appendix). PBMCs (>85% myeloid) that were obtained at the time of diagnosis from four patients with CML were also exposed to imatinib, a selective tyrosine kinase inhibitor.25 In contrast to untreated cells, imatinib-treated cells increased NHE-1 levels and Bcl-xL deamidation in response to DNA damage (Figure 3E and 3F). These results demonstrate a causal link between tyrosine kinase activity and repression of the Bcl-xL deamidation pathway.
Imatinib and the JAK2 inhibitors inhibit the activity of several kinases in addition to BCR-ABL and JAK2, respectively, raising the possibility that inhibition of other kinases may contribute to the observed effects. We therefore studied a patient who had become resistant to imatinib as a consequence of an E255V mutation in the BCR-ABL kinase domain. Imatinib-treated PBMCs from this patient did not have increased NHE-1 levels in response to etoposide or Bcl-xL deamidation in response to either etoposide or irradiation (Figure 4A and 4B). However, the effects of imatinib resistance could be bypassed by NHE-1 overexpression, which caused increased intracellular pH and apoptosis (Figure 4C and 4D), or by enforced alkalinization, which caused increased Bcl-xL deamidation and apoptosis (Figure 12 in the Supplementary Appendix). These data demonstrate that BCR-ABL kinase activity is essential for inhibition of the Bcl-xL deamidation pathway in CML cells.
Discussion
Deamidation of internal asparagine or glutamine residues can have a profound influence on protein function and has been implicated in a wide range of biologic processes.26-28 Rates of asparagine deamidation were initially thought to be fixed and determined solely by the structural context of a given asparagine residue, but an active role in the regulation of biologic processes was suggested by the observations that DNA damage can trigger rapid deamidation of Bcl-xL 12 and that Bcl-xL deamidation plays a central role in the apoptotic response of normal mouse thymocytes to DNA damage.13,14
In our study, we found that the signaling pathway leading from DNA damage to Bcl-xL deamidation and consequent apoptosis is inhibited in two myeloproliferative disorders associated with different tyrosine kinases and activated by distinct mechanisms (Figure 5Figure 5
Effects of Inhibition of Bcl-xL Deamidation in Patients with CML or Polycythemia Vera.). We demonstrated this defect in cells from all 20 patients bearing either BCR-ABL or the JAK2 V617F mutation, whereas no defect was observed in cells expressing other oncogenic tyrosine kinases, such as NPM-ALK. To suppress the apoptotic response to DNA damage, it is insufficient for BCR-ABL or mutant JAK2 merely to up-regulate or maintain Bcl-xL expression levels. In addition, both oncogenic tyrosine kinases must prevent deamidation of Bcl-xL to preserve its antiapoptotic function. These observations not only shed light on the accumulation of DNA damage that is characteristic of these cancers29,30 but also have potential therapeutic relevance.CML and polycythemia vera are associated with an increased risk of leukemic transformation, which is thought to reflect the accrual of additional genetic lesions. However, it is not clear why stem cells from patients with chronic-phase CML and polycythemia vera are prone to accumulate DNA damage.29 Normal cells undergo many DNA strand breaks per genome per cell division, and adequate DNA repair mechanisms, combined with the removal of damaged cells by apoptosis, are therefore essential for homeostasis.31 Inhibition of the Bcl-xL deamidation pathway in chronic-phase CML and polycythemia vera provides a mechanism for circumventing the apoptotic response and permitting accumulation of DNA damage within the malignant clone.
It has been reported that cells expressing oncogenic tyrosine kinases, including BCR-ABL, are resistant to DNA damage.32-34 Resistance to DNA-damaging agents depends on BCR-ABL catalytic activity.32 Consistent with this finding, the combination of antileukemic chemotherapy with the tyrosine kinase inhibitor imatinib produces increased or synergistic apoptosis.35-38 Our results shed light on the molecular basis for the effectiveness of such combination therapies. Inhibition of BCR-ABL by imatinib is associated with increased levels of proapoptotic BH3-only proteins, such as Bim and Bad.39-41 The activity of these molecules is constrained by their binding to Bcl-xL. Optimal apoptosis in response to DNA damage requires that imatinib restore the normal Bcl-xL deamidation pathway, thus minimizing sequestration by Bcl-xL and maximizing apoptosis in response to DNA-damaging agents.
The use of tyrosine kinase inhibitors in CML faces two main challenges. Acquired resistance to imatinib therapy can result in relapse, often as a consequence of kinase-domain mutations in BCR-ABL.42 In addition, treatment of CML with tyrosine kinase inhibitors is usually associated with persistence of residual disease, which is thought to reflect quiescent BCR-ABL–positive stem cells that resist current tyrosine kinase inhibitors.9-11 It is therefore notable that an increase in the expression of NHE-1 by a factor of 2 to 3 was sufficient to increase Bcl-xL deamidation and triple the level of apoptosis in imatinib-resistant CML cells (Figure 4D). Therefore, targeted stimulation of Bcl-xL deamidation provides a potential route for circumventing resistance to tyrosine kinase inhibitors and perhaps also for eradicating leukemic stem cells.
The NHE-1 antiport itself represents a potential therapeutic target. Small-molecule inhibitors already exist, although the development of agonists may be more challenging. The NHE-1 antiport can also be activated by phosphorylation,43 which suggests the possibility of other therapeutic approaches. The fact that modulation of the NHE-1–Bcl-xL signaling pathway can bypass resistance to apoptosis in patients with CML and polycythemia vera raises the possibility of new therapeutic approaches that could be of general relevance to any cancer in which Bcl-xL plays an important role in genotoxic resistance. Indeed, Bcl-xL expression in a wide range of cancers has a striking correlation with resistance to genotoxic compounds,44 which suggests that our findings are likely to have relevance well beyond the myeloproliferative disorders.
Supported by the Association for International Cancer Research, the Biotechnology and Biological Sciences Research Council, the U.K. Leukaemia Research Fund, the Wellcome Trust, the U.K. Medical Research Council, Cancer Research UK, the National Institute for Health Research Cambridge Biomedical Research Center, and the U.S. Leukemia and Lymphoma Society.
No potential conflict of interest relevant to this article was reported.
Drs. Green and Alexander contributed equally to this article.
We thank Geoff Morgan and Mary Janes for their assistance with fluorescence-activated cell sorting and cell culture, respectively; Dr. Suzanne Turner for providing the NPM–ALK construct; the Addenbrooke's Haematological Disorders Sample Bank for storage and provision of samples; and Drs. J. Lyons and M. Squires for providing JAK2 inhibitors.
Source Information
From the Laboratory of Lymphocyte Signalling and Development, Babraham Institute (R.Z., D.R.A.), and the Cambridge Institute for Medical Research, Addenbrooke's Hospital (G.A.F., P.A.B., L.M.S., B.J.P.H., A.R.G.), University of Cambridge, Cambridge, United Kingdom.
Address reprint requests to Dr. Zhao at the Laboratory of Lymphocyte Signalling and Development, Babraham Institute, Cambridge CB2 4AT, United Kingdom, or at rui.zhao@bbsrc.ac.uk; or to Dr. Green at the Cambridge Institute for Medical Research, Hills Rd., Cambridge CB2 2XY, United Kingdom, or at arg1000@cam.ac.uk.
- References
References
1
Goldman JM ,Melo JV . Chronic myeloid leukemia -- advances in biology and new approaches to treatment. N Engl J Med 2003;349:1451-1464
Full Text | Web of Science | Medline2
Campbell PJ ,Green AR . The myeloproliferative disorders. N Engl J Med 2006;355:2452-2466
Full Text | Web of Science | Medline3
Scott LM ,Tong W ,Levine RL , et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459-468
Full Text | Web of Science | Medline4
Amarante-Mendes GP ,McGahon AJ ,Nishioka WK ,Afar DE ,Witte ON ,Green DR . Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene 1998;16:1383-1390
CrossRef | Web of Science | Medline5
Oetzel C ,Jonuleit T ,Gotz A , et al. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. Clin Cancer Res 2000;6:1958-1968
Web of Science | Medline6
Silva M ,Richard C ,Benito A ,Sanz C ,Olalla I ,Fernandez-Luna JL . Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med 1998;338:564-571
Full Text | Web of Science | Medline7
Garcon L ,Rivat C ,James C , et al. Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood 2006;108:1551-1554
CrossRef | Web of Science | Medline8
Skorski T . BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene 2002;21:8591-8604
CrossRef | Web of Science | Medline9
Holyoake T ,Jiang X ,Eaves C ,Eaves A . Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999;94:2056-2064
Web of Science | Medline10
Copland M ,Hamilton A ,Elrick LJ , et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006;107:4532-4539
CrossRef | Web of Science | Medline11
Jorgensen HG ,Allan EK ,Jordanides NE ,Mountford JC ,Holyoake TL . Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007;109:4016-4019
CrossRef | Web of Science | Medline12
Deverman BE ,Cook BL ,Manson SR , et al. Bcl-xL deamidation is a critical switch in the regulation of the response to DNA damage. Cell 2002;111:51-62
CrossRef | Web of Science | Medline13
Zhao R ,Yang FT ,Alexander DR . An oncogenic tyrosine kinase inhibits DNA repair and DNA-damage-induced Bcl-xL deamidation in T cell transformation. Cancer Cell 2004;5:37-49
CrossRef | Web of Science | Medline14
Zhao R ,Oxley D ,Smith TS ,Follows GA ,Green AR ,Alexander DR . DNA damage-induced Bcl-xL deamidation is mediated by NHE-1 antiport regulated intracellular pH. PLoS Biol 2006;5:e1-e1
CrossRef | Web of Science15
Chang CY ,Lin YM ,Lee WP ,Hsu HH ,Chen EI . Involvement of Bcl-X(L) deamidation in E1A-mediated cisplatin sensitization of ovarian cancer cells. Oncogene 2006;25:2656-2665
CrossRef | Web of Science | Medline16
Jones AV ,Kreil S ,Zoi K , et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106:2162-2168
CrossRef | Web of Science | Medline17
Baxter EJ ,Scott LM ,Campbell PJ , et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061
CrossRef | Web of Science | Medline18
James C ,Ugo V ,Le Couedic JP , et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148
CrossRef | Web of Science | Medline19
Kralovics R ,Passamonti F ,Buser AS , et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790
Full Text | Web of Science | Medline20
Levine RL ,Wadleigh M ,Cools J , et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397
CrossRef | Web of Science | Medline21
Scott LM ,Scott MA ,Campbell PJ ,Green AR . Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006;108:2435-2437
CrossRef | Web of Science | Medline22
Jaiswal S ,Traver D ,Miyamoto T ,Akashi K ,Lagasse E ,Weissman IL . Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias. Proc Natl Acad Sci U S A 2003;100:10002-10007
CrossRef | Web of Science | Medline23
Jamieson CH ,Ailles LE ,Dylla SJ , et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657-667
Full Text | Web of Science | Medline24
Koschmieder S ,Gottgens B ,Zhang P , et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 2005;105:324-334
CrossRef | Web of Science | Medline25
Druker BJ ,Tamura S ,Buchdunger E , et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-566
CrossRef | Web of Science | Medline26
Hoffmann C ,Pop M ,Leemhuis J ,Schirmer J ,Aktories K ,Schmidt G . The Yersinia pseudotuberculosis cytotoxic necrotizing factor (CNFY) selectively activates RhoA. J Biol Chem 2004;279:16026-16032
CrossRef | Web of Science | Medline27
Robinson NE, Robinson AB. Molecular clocks: deamidation of asparaginyl and glutaminyl residues in peptides and proteins. Cave Junction, OR: Althouse Press, 2004.
28
Moss CX ,Matthews SP ,Lamont DJ ,Watts C . Asparagine deamidation perturbs antigen presentation on class II major histocompatibility complex molecules. J Biol Chem 2005;280:18498-18503
CrossRef | Web of Science | Medline29
Melo JV ,Barnes DJ . Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007;7:441-453
CrossRef | Web of Science | Medline30
Plo I ,Nakatake M ,Malivert L , et al. JAK2 stimulates homologous recombination and genetic instability. Blood 2008;112:1402-1412
CrossRef | Web of Science | Medline31
McGlynn P ,Lloyd RG . Recombinational repair and restart of damaged replication forks. Nat Rev Mol Cell Biol 2002;3:859-870
CrossRef | Web of Science | Medline32
Bedi A ,Barber JP ,Bedi GC , et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 1995;86:1148-1158
Web of Science | Medline33
Nishii K ,Kabarowski JH ,Gibbons DL , et al. ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Oncogene 1996;13:2225-2234
Web of Science | Medline34
Amarante-Mendes GP ,Naekyung Kim C ,Liu L , et al. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood 1998;91:1700-1705
Web of Science | Medline35
Fang G ,Kim CN ,Perkins CL , et al. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 2000;96:2246-2253
Web of Science | Medline36
Slupianek A ,Hoser G ,Majsterek I , et al. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol 2002;22:4189-4201
CrossRef | Web of Science | Medline37
Topaly J ,Zeller WJ ,Fruehauf S . Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 2001;15:342-347
CrossRef | Web of Science | Medline38
Kano Y ,Akutsu M ,Tsunoda S , et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001;97:1999-2007
CrossRef | Web of Science | Medline39
Aichberger KJ ,Mayerhofer M ,Krauth MT , et al. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res 2005;65:9436-9444
CrossRef | Web of Science | Medline40
Kuroda J ,Puthalakath H ,Cragg MS , et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A 2006;103:14907-14912
CrossRef | Web of Science | Medline41
Kuroda J ,Kimura S ,Strasser A , et al. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ 2007;14:1667-1677
CrossRef | Web of Science | Medline42
Schiffer CA . BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 2007;357:258-265
Full Text | Web of Science | Medline43
Putney LK ,Denker SP ,Barber DL . The changing face of the Na+/H+ exchanger, NHE1: structure, regulation, and cellular actions. Annu Rev Pharmacol Toxicol 2002;42:527-552
CrossRef | Web of Science | Medline44
Amundson SA ,Myers TG ,Scudiero D ,Kitada S ,Reed JC ,Fornace AJ Jr . An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000;60:6101-6110
Web of Science | Medline
- Citing Articles (18)
Citing Articles
1
Elisa Rumi, Ashot Harutyunyan, Chiara Elena, Daniela Pietra, Thorsten Klampfl, Klaudia Bagienski, Tiina Berg, Ilaria Casetti, Cristiana Pascutto, Francesco Passamonti, Robert Kralovics, Mario Cazzola. (2011) Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm. American Journal of Hematology 86:12, 974-979
CrossRef2
Cui-Juan Qian, Jun Yao, Jian-Min Si. (2011) Nuclear JAK2: Form and Function in Cancer. The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology 294:9, 1446-1459
CrossRef3
Weina Jin, Qinghua Li, Yani Lin, Ying Lu, Huawen Li, Lihong Wang, Ronghua Hu, Li Ma, Jianxiang Wang, Tianxiang Pang. (2011) Reversal of Imatinib resistance in BCR-ABL-positive leukemia after inhibition of the Na+/H+ exchanger. Cancer Letters 308:1, 81-90
CrossRef4
Linda M. Scott. (2011) The JAK2 exon 12 mutations: A comprehensive review. American Journal of Hematology 86:8, 668-676
CrossRef5
M Nakatake, B Monte-Mor, N Debili, N Casadevall, V Ribrag, E Solary, W Vainchenker, I Plo. (2011) JAK2V617F negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene
CrossRef6
Omar Abdel-Wahab. (2011) Genetics of the myeloproliferative neoplasms. Current Opinion in Hematology 18:2, 117-123
CrossRef7
Heba Mehdawi, Moussa Alkhalaf, Islam Khan. (2010) Role of Na+/H+ exchanger in resveratrol-induced growth inhibition of human breast cancer cells. Medical Oncology
CrossRef8
C. Harrison. (2010) Rethinking Disease Definitions and Therapeutic Strategies in Essential Thrombocythemia and Polycythemia Vera. Hematology 2010:1, 129-134
CrossRef9
J. Li, D. Spensberger, J. S. Ahn, S. Anand, P. A. Beer, C. Ghevaert, E. Chen, A. Forrai, L. M. Scott, R. Ferreira, P. J. Campbell, S. P. Watson, P. Liu, W. N. Erber, B. J. P. Huntly, K. Ottersbach, A. R. Green. (2010) JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood 116:9, 1528-1538
CrossRef10
Stephen T Oh, Jason Gotlib. (2010) JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Review of Hematology 3:3, 323-337
CrossRef11
J. L. Spivak. (2010) An inconvenient truth. Blood 115:14, 2727-2728
CrossRef12
P. A. Beer, F. Delhommeau, J. P. LeCouedic, M. A. Dawson, E. Chen, D. Bareford, R. Kusec, M. F. McMullin, C. N. Harrison, A. M. Vannucchi, W. Vainchenker, A. R. Green. (2010) Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 115:14, 2891-2900
CrossRef13
Lizz F. Grimwade, Lisa Happerfield, Colin Tristram, Gary McIntosh, Mark Rees, Anthony J. Bench, Elaine M. Boyd, Marie Hall, Amy Quinn, Nigel Piggott, Paul Scorer, Mike A. Scott, Wendy N. Erber. (2009) Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms. British Journal of Haematology 147:4, 495-506
CrossRef14
Mark A. Dawson, Andrew J. Bannister, Berthold Göttgens, Samuel D. Foster, Till Bartke, Anthony R. Green, Tony Kouzarides. (2009) JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin. Nature 461:7265, 819-822
CrossRef15
A. Navarro, T. Diaz, A. Martinez, A. Gaya, A. Pons, B. Gel, C. Codony, G. Ferrer, C. Martinez, E. Montserrat, M. Monzo. (2009) Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood 114:14, 2945-2951
CrossRef16
J M Goldman, A R Green, T Holyoake, C Jamieson, R Mesa, T Mughal, F Pellicano, D Perrotti, R Skoda, A M Vannucchi. (2009) Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. Leukemia 23:10, 1708-1715
CrossRef17
Isabelle Plo, William Vainchenker. (2009) Molecular and Genetic Bases of Myeloproliferative Disorders: Questions and Perspectives. Clinical Lymphoma, Myeloma & Leukemia 9:0, S329-S339
CrossRef18
P. A. Beer, A. R. Green. (2009) Pathogenesis and management of essential thrombocythemia. Hematology 2009:1, 621-628
CrossRef
